NASH is the most severe form of non-alcoholic fatty liver disease and is characterised by the presence of an abnormal accumulation of fat in the liver. In some individuals, the disease can progress to liver cell injury (hepatocellular ballooning) and inflammation. As NASH evolves, over time it can result in excessive scarring in the liver (fibrosis), a natural response to injury which can eventually lead to liver cirrhosis or liver cancer.

Whether an individual develops NASH is heavily influenced by lifestyle; chronic excessive calorie intake and sedentary activity are well-known risk factors. In that sense, NASH differs from other fatty liver diseases caused by alcohol abuse or medication side effects and the ongoing obesity epidemic therefore makes NASH a serious burden of disease with an urgent need for effective treatments.

As a result of the increasing demand for participants in NASH clinical research studies, most of the data of patients diagnosed with NASH in frequently targeted geographical areas have become exhausted. Therefore, the yet undiagnosed pool of NASH patients is critical for conducting large pivotal trials in the near future. To address this major challenge, we developed a unique and efficient patient care pathway methodology that looks at typical pre-NASH classification risk factors, in close collaboration with our proprietary NASH Clinical Network. Our highly experienced NASH team is ready to provide you with the perfect tailor-made solution for your NASH clinical trial.

Martin Czakon

Martin Czakon

Director of NASH